Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Palomar, Syneron Settle Patent Suits
Sep 2011
BURLINGTON, Mass., and YOKEAM, Israel, Sept. 23, 2011 — Cosmetic laser maker Palomar Medical Technologies Inc. of Burlington has announced the receipt of $31 million plus royalties from aesthetic device company Syneron Medical Ltd. of Yokeam in a comprehensive settlement agreement of their patent-infringement dispute over hair-removal systems. The settlement includes two nonexclusive patent license agreements.

Under the first agreement, Palomar granted Syneron and its Candela unit a worldwide, irrevocable license to US Patent Nos. 5,735,844 and 5,595,568 for professional laser- and lamp-based hair removal technology.

Under the second agreement, Palomar granted Syneron and affiliates a nonexclusive license in the US to the same two patents for consumer home-use lamp-based hair removal products. Palomar received a license to certain Syneron and Candela patents.

The settlement ends a dispute that started in 2006.

Under Palomar’s license agreement with the General Hospital Corp. in Boston, Palomar will pay 40 percent of the settlement payments from Candela and Syneron, minus its legal costs.

For more information, visit: or  

AmericasBiophotonicsBusinessCandela Corp.cosmetic lasersGeneral Hospital removal systemsIsraellamp-based hair removalMassachusettsMiddle EastPalomar Medical Technologiespatent infringement disputeSyneron Medical Ltd.lasers

Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2019 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.